Lifecore Biomedical Inc. (LFCR)
LFCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-KT (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2024-05-26, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000009/0001005286-26-000009-index.htm. Net income: SEC 10-KT (us-gaap:NetIncomeLoss), fiscal year ended 2024-05-26.
Profile
| Field | Value |
|---|---|
| Ticker | LFCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001005286 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $128.3M |
| Net income | $12.0M |
| Operating income | -$8.8M |
| Net margin | 9.4% |
| Operating margin | -6.9% |
| Revenue growth | +24.2% |
| Cash | $8.5M |
| Total assets | $254.0M |
| P/E (computed) | 20.2× |
| P/S (computed) | 1.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $23.0M cash; operating cash flow $2.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 37,905,846 (2026-10-28); 37,466,352 a year earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-08-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $25.3M | -$40.1M | $6.9M | $23.0M | $161.0M | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2027 2026-06-30 | $34.2M | -$6.2M | -$2.2M | $17.2M | $155.1M | Needs four quarters | 10-Q 2026-08-05 |
| Q3 2026 2026-03-31 | $23.2M | -$15.0M | $4.7M | $20.8M | $148.7M | Needs four quarters | 10-Q 2026-05-06 |
| Q1 2026 2025-09-30 | $31.1M | -$10.0M | $1.8M | $18.9M | $136.0M | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-05-25 | $36.4M | -$1.1M | $5.3M | $8.3M | $130.4M | $128.9M | 10-Q 2026-08-05 |
| Q3 2025 2025-02-23 | $35.2M | -$14.8M | $1.2M | $5.4M | $124.9M | $130.3M | 10-Q 2026-05-06 |
| Q2 2025 2024-11-24 | $32.6M | -$6.6M | -$6.1M | $9.5M | $111.3M | $130.9M | 10-Q 2025-01-02 |
| Q1 2025 2024-08-25 | $24.7M | -$16.2M | -$613K | $5.5M | $106.3M | $128.4M | 10-Q 2025-11-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-09-30 |
| Latest annual report | 10-KT | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFM14A | 2026-11-13 |
Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.9% |
| 1 month | 0.0% |
| 3 months | +35.7% |
| Year to date | -21.5% |
| 1 year | -18.6% |
| From 52-week high | -27.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CAMP | CAMP4 Therapeutics Corporation | $3.86 | +1.58% | $242.2M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
| FTH | Faeth Therapeutics Inc. | $9.28 | -7.48% | $239.8M |
| ARCT | Arcturus Therapeutics Holdings Inc. | $8.31 | -0.60% | $239.5M |
| QTTB | Q32 Bio Inc. | $8.29 | -4.82% | $248.1M |
| AMRN | Amarin Corporation plc | $11.31 | -0.62% | $233.4M |
| VNDA | Vanda Pharmaceuticals Inc. | $3.81 | -4.51% | $230.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier